RG 7167

Drug Profile

RG 7167

Alternative Names: CH4987655; CIF - Chugai; R7167; RG7167; RO-4987655

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Roche
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Cytochrome inhibitors; Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Dec 2014 Roche completes a phase I trial for Solid tumours (late-stage disease, monotherapy) in France, Germany, Netherlands, Spain and the UK (NCT00817518)
  • 24 Jul 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in France (PO)
  • 24 Jul 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top